Related references
Note: Only part of the references are listed.BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia
S-S Chen et al.
LEUKEMIA (2016)
ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients
Todd Covey et al.
CANCER RESEARCH (2015)
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson et al.
NATURE MEDICINE (2015)
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity
Holbrook E. Kohrt et al.
BLOOD (2014)
Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment
Xiaohui Zheng et al.
CANCER CELL INTERNATIONAL (2014)
Phase II Evaluation of VDC-1101 in Canine Cutaneous T-Cell Lymphoma
M. A. Morges et al.
JOURNAL OF VETERINARY INTERNAL MEDICINE (2014)
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
Susan O'Brien et al.
LANCET ONCOLOGY (2014)
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity
S. Cheng et al.
LEUKEMIA (2014)
Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study
Cheryl A. London et al.
PLOS ONE (2014)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Gene Profiling of Canine B-Cell Lymphoma Reveals Germinal Center and Postgerminal Center Subtypes with Different Survival Times, Modeling Human DLBCL
Kristy L. Richards et al.
CANCER RESEARCH (2013)
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi
Robbert Hoogeboom et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis
Munevver Cinar et al.
LEUKEMIA RESEARCH (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Comparative Gene Expression Profiling Identifies Common Molecular Signatures of NF-κB Activation in Canine and Human Diffuse Large B Cell Lymphoma (DLBCL)
Manikhandan A. V. Mudaliar et al.
PLOS ONE (2013)
B cell receptor signaling in chronic lymphocytic leukemia
Jan A. Burger et al.
TRENDS IN IMMUNOLOGY (2013)
Molecular Profiling Reveals Prognostically Significant Subtypes of Canine Lymphoma
A. M. Frantz et al.
VETERINARY PATHOLOGY (2013)
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
Sabine Ponader et al.
BLOOD (2012)
Self-antigen recognition by follicular lymphoma B-cell receptors
Kacey L. Sachen et al.
BLOOD (2012)
Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases
Anastasia Hadzidimitriou et al.
BLOOD (2011)
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E. M. Herman et al.
BLOOD (2011)
Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer
Cheryl A. London et al.
PLOS ONE (2011)
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
Sarah E. M. Herman et al.
BLOOD (2010)
Modeling Opportunities in Comparative Oncology for Drug Development
Ira K. Gordon et al.
ILAR JOURNAL (2010)
Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma
Barbara C. Ruetgen et al.
LEUKEMIA RESEARCH (2010)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
Mara Compagno et al.
NATURE (2009)
Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA
Charles C. Chu et al.
BLOOD (2008)
ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia
Liguang Chen et al.
BLOOD (2008)
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors
Anna Liza C. Agero et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
The role of antigenic drive and tumor-infiltrating accessory cells in the pathogenesis of Helicobacter-induced mucosa-associated lymphoid tissue lymphoma
A Mueller et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia
BT Messmer et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Survival of resting mature B lymphocytes depends on BCR signaling via the Igα/β heterodimer
M Kraus et al.
CELL (2004)
Principles of treatment for canine lymphoma
SN Ettinger
CLINICAL TECHNIQUES IN SMALL ANIMAL PRACTICE (2003)
Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes
RC Burnett et al.
VETERINARY PATHOLOGY (2003)
Share Paper
